Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624723 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT05624723 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 43 participants.
The verdict
NCT05624723, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
Interventions
- DRUG INCB054707
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2024-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05624723
The ClinicalTrials.gov registry entry for NCT05624723 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB054707 is the first listed.
NCT05624723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05624723 about?
NCT05624723 is a clinical study titled "Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis". This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
What is the current status of trial NCT05624723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2023-01-12. Estimated completion is 2024-02-07.
What interventions are being tested in trial NCT05624723?
The interventions under investigation include: INCB054707 (DRUG).
Who is sponsoring clinical trial NCT05624723?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.